Suppression of the motor deficit in a mucolipidosis type IV mouse model by bone marrow transplantation

Marquis T. Walker, Craig Montell

Research output: Contribution to journalArticlepeer-review


Mucolipidosis IV (MLIV) is a severe lysosomal storage disorder, which results from loss of the TRPML1 channel. MLIV causes multiple impairments in young children, including severe motor deficits. Currently, there is no effective treatment. Using a Drosophila MLIV model, we showed previously that introduction of trpml+in phagocytic glia rescued the locomotor deficit by removing early dying neurons, thereby preventing amplification of neuronal death from cytotoxicity. Because microglia, which are phagocytic cells in the mammalian brain, are bone marrow derived, and cross the blood-brain barrier, we used a mouse MLIV model to test the efficacy of bone marrow transplantation (BMT). We found that BMT suppressed the reduced myelination and the increased caspase-3 activity due to loss of TRPML1. Using a rotarod test, we demonstrated that early BMT greatly delayed the motor impairment in the mutant mice. These data offer the possibility that BMT might provide the first therapy for MLIV.

Original languageEnglish (US)
Pages (from-to)2752-2761
Number of pages10
JournalHuman Molecular Genetics
Issue number13
StatePublished - 2016

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Genetics(clinical)


Dive into the research topics of 'Suppression of the motor deficit in a mucolipidosis type IV mouse model by bone marrow transplantation'. Together they form a unique fingerprint.

Cite this